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Research in which children undergo genetic testing for predisposition to adult-onset 
diseases or disorders can lead to a better understanding of these conditions. It can 
possibly also help encourage early detection and the development of clinical and 
preventive interventions for those found to be at increased hereditary risk. Increasingly, 
predisposition testing is becoming part of pediatric genetic research. However, the paucity 
of normative texts about the conduct of pediatric research using predisposition genetic 
testing generates complex legal and ethical issues. Drawing on the current texts that 
govern predisposition genetic testing in research and the norms of pediatric research, we 
outline points of consensus and divergence as well as recommendations regarding 
predisposition genetic testing in pediatric research.  
 
 
For few single gene diseases1, 
predisposition genetic tests offer clear 
predictions because they offer information 
about whether an asymptomatic individual is 
a carrier of the mutation which, in 100% of 
cases, causes a specific disease that will 
manifest during the individual’s life.  For 
most conditions, however, predisposition 
genetic tests identify an increased 
susceptibility to a particular disease or, 
often, to several diseases which form a 
hereditary syndrome.  
 
 
 this last case, genetic susceptibility 
hy an ethical concern about predisposition 
 
In
increases the risk of developing the 
disease(s) often at a younger than usual age 
of onset2. The manifestation of the disease 
may depend on the interaction of several 
genes or on environmental factors3. In 
addition to clinical practice uses, 
researchers are developing research 
protocols for genetic testing. Clinical genetic 
information may be distinguished from 
research results; research results are likely 
to be much more uncertain, ambiguous, and 
may involve tests which have not been 
clinically validated.  
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medicine4 and, undoubtedly, children will be 
recruited for research for a variety of 
reasons:  they may come from families with 
a history of adult-onset diseases who are 
likely to be considered participants in 
predisposition genetic testing research; a 
growing number of diseases are known to 
have a genetic component5; and 
accumulating evidence demonstrates that 
risk factors during childhood contribute to 
several late onset disorders6. There are 
some guidelines about the inclusion of 
children in research7 but very few refer 
specifically to genetic research.  
 
While individual results are not given in most 
owever, predisposition test results may 
 the clinical setting, the principal 
ore recently, certain national organizations 
research environments, the availability of 
predisposition genetic test results from 
genetic research can be problematic for a 
variety of reasons. The relationship between 
the research finding and the risk of 
developing a disease may be unclear. As 
mentioned above, research testing may not 
have clinical level accuracy. The result may 
identify either mutations in asymptomatic 
individuals or a susceptibility to an illness for 
which there is no known treatment (curative 
or preventative)8. Furthermore, if 
researchers intend on providing individual 
results to participants, there is an 
expectation that, to understand the 
implications of the individual predisposition 
test results, subjects should undergo genetic 
counselling, which in a research 
environment is not easily accessible. In 
addition, genetic information is often 
considered problematic because it reveals 
both individual and familial information9. 
Also, mere knowledge of hereditary disease 
predisposition and individual test results can 
have psychological, social, or financial 
consequences10. Even in clinical settings, 
where the issue is whether to perform 
predisposition genetic tests on children, 
several difficult ethical questions are raised, 
for example, whether, when, and by whom 
children should be informed about their 
genetic test results11.  Disclosing the results 
of the tests to parents may contravene the 
child’s right not to know the information 
(right not to know/right to an open future).  
 
H
also be beneficial clinically since they can 
promote targeted screening (if there are 
appropriate screening needs), help make 
informed decisions about carrier status 
(notably about the question of planning a 
pregnancy) and help people take control of 
their health. They can also provide a sense 
of relief from uncertainty about whether 
hereditary risks are present, as well as end 
the need for intensive screening for those 
without a familial mutation. Tests results can 
help people prepare psychologically and 
practically for the future; however, they may 
also raise uncertainties12. In short, the 
legitimacy and acceptability of predisposition 
testing is dependent on the context and the 
population involved13.  
 
In
justification for the use of predisposition 
tests in pediatrics is that testing is in the 
“best interest” of the child.  If the test reveals 
the presence of a deleterious mutation, and 
there are treatments or effective preventive 
measures which can be initiated during 
childhood, this could be clearly beneficial to 
the child14. For example, among families 
considered at-risk due to family history or 
prior positive test results in affected adult 
relatives, predisposition genetic testing has 
been used to identify children carrying a 
mutation that makes them susceptible to a 
particular type of colon cancer, familial 
adnenomatous polyposis15.  In this case, the 
use of predisposition genetic tests is 
considered legitimate because the cancer 
may develop before the child reaches the 
age of majority and also because 
identification allows for early interventions 
that reduce morbidity and mortality, such as 
periodic monitoring and, if the disease 
develops, earlier treatment. It also stops the 
monitoring of those not at risk.  
 
M
have claimed that it may be legitimate at 
times to use predisposition testing in the 
broader context of pediatric research. For 
example, the American Academy of 
Pediatrics’ guidelines on ethical issues in 
genetic testing involving children (published 
in 2001 and reaffirmed in 2004) mention 
that, while it is necessary to limit the use of 
genetic tests for late-onset diseases among 
children, research in this domain should be 
encouraged16. Also, the Bioethics Advisory 
Committee of Singapore has suggested that 
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genetic tests (without specific reference to 
genetic predisposition tests) can be carried 
out on vulnerable populations in a research 
context when the research is sufficiently 
important and when it cannot be done 
without the vulnerable population17. 
 
With this in mind, we will briefly set out the 
context in which predisposition testing in 
pediatric research is useful (I).  Then, we will 
examine the ethical and legal norms 
concerning the use of these predisposition 
tests which limit to pediatric research (II).  
Throughout, we will review whether it is 
legitimate, according to current normative 
frameworks18, to use predisposition tests in 
pediatric research and, if so, under which 
conditions. Our analysis focuses on 
normative texts related to human genetics 1) 
adopted since 1995, 2) be they international, 
European, Canadian or American, and 3) 
specifically address the use of predictive 
tests in research, or, more generally, genetic 
research involving children.  To conclude, 
we present our key findings as well as our 
position on the use of genetic predisposition 
tests in pediatric research. 
      
With respe  to children, a fundamental 
Research directed at childhood and early 
T netic 
ks   
osition tests in 
I. Context  
 
ct
principle in law and ethics is the 
consideration of the “best interests” of the 
child19; this principle should guide decision-
making about the child’s care. In pediatric 
research, this principle is reflected, on one 
hand, in the duty of special protection for 
children, while recognizing their specific 
vulnerability20.  For example, their 
autonomy—i.e. their capacity to make 
decisions and to protect their own 
interests—is not completely developed and 
their ability to comprehend important 
aspects of research will vary based on their 
stage of development21.  On the other hand, 
it has also been recognized that acting in the 
best interests of the child means not 
excluding them from research22. Provided 
that the potential risks and benefits are 
balanced, it is generally desirable that 
research be carried out:  
 
precursors of adult disease relies on studies 
occurring during childhood, and as genetic 
contributors to common complex diseases are 
identified, a broader range of conditions will be 
studied. In addition, study of genetic variation 
within families is an important methodological 
approach in genetic research. As a result, children 
are important participants in genetic research.23
 
oday  pediatric research, including ge,
rcresea h, is considered essential and 
beneficial for improving the health and well-
being of children24. It is useful to examine 
the normative texts regarding the use of 
predisposition genetic testing in research 
and the normative rules governing research 
participation of children. 
 
I. Normative FrameworI
 
Is it legitimate to use predisp
pediatric research?  If so, in what context? 
What conditions must be met? Current 
normative documents do not explicitly focus 
on the topic of predisposition testing in 
children25. Thus, in the absence of specific 
research guidelines, it is important to 
determine (1) whether the use of 
predisposition genetic testing in research is 
generally permissible; and then (2) if there 
are any special considerations regarding 
pediatric genetic research that may be 
applicable to predisposition tests.  
 
1) Predisposition Genetic Testing in 
 
ew l or national normative 
Research 
internationaF
instruments specifically address the issue of 
using predisposition tests in research, with 
the exception of: the 1997 Convention on 
Human Rights and Biomedicine26 by the 
Council of Europe, Testing for Genetic 
Predisposition to Adult Onset Disease27 
guidelines by the International Federation of 
Gynecology and Obstetrics (FIGO), and the 
Ethical Issues With Genetic Testing in 
Pediatrics28 by the American Academy of 
Pediatrics’. 
 
Under certain circumstances and conditions, 
ctive of genetic diseases or 
which serve either to identify the subject as a 
the Convention on Human Rights and 
Biomedicine29  legitimizes the use of 
predisposition tests (the Convention uses 
the expression “predictive genetic test”) in 
medical research:  
 
Tests which are predi
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carrier of a gene responsible for a disease or to 
detect a genetic predisposition or susceptibility to 
a disease may be performed only for health 
purposes or for scientific research linked to health 
purposes, and subject to appropriate genetic 
counselling.30  
 
Specifically, according to the explanatory 
report to the Convention, it is necessary that 
the research pursue one of the two following 
goals: develop medical treatment or 
increase the ability to prevent diseases31. 
However, it is also mentioned that when 
predisposition tests seek to detect late-onset 
serious illnesses for which there is no 
treatment, then the use of these tests must 
be limited, even in a research context, to 
exceptional cases. “Exceptional cases” are 
not defined by either the Convention or the 
related report and these texts do not contain 
any additional guidance which might justify 
the exceptional usage of predisposition tests 
for research32. The reason for this limitation 
on the use of predisposition tests is that they 
risk violating the principles of free 
participation and of respect for privacy33. 
Generally, the Convention specifies that 
genetic tests can occur only after the 
individual in question has given his/her 
consent and after there has been 
appropriate genetic counselling34. However, 
the Convention does not specify whether 
appropriate genetic counselling is applicable 
in the clinical or research context, or both. 
Nevertheless, genetic counselling is likely 
more accessible in a clinical setting35.  
 
he FIGO guidelines provide commeT ntary 
about the use of certain predisposition tests 
in research. The guidelines emphasize that 
no susceptibility test for genetic disease 
should be done or proposed in the absence 
of informed consent36. Also, the 
recommendations acknowledge that 
obtaining informed consent for 
predisposition testing is different because of 
the complex gene-gene and gene-
environment interactions that influence the 
manifestation of the given disease37. 
However, they do not provide guidance on 
this issue. Again, pre- and post-test genetic 
counselling is recommended38. But, as 
noted in the Convention, this 
recommendation is primarily applicable for 
predisposition tests occurring in a clinical 
setting.  FIGO also affirms that the 
“[c]onfidentiality of the testing and the results 
is critical”39.  FIGO recommends that 
researchers indicate to participants that 
there is the possibility of specifying if they 
would like to know the results of their 
genetic predisposition40. Yet, in many 
research environments, the reliability and 
predictive value of genetic tests are often 
unknown or unclear and still under 
development.  Nevertheless, FIGO 
guidelines state that participants “should 
have the opportunity to designate whether or 
not genetically related family members 
should have access to the information if they 
so desire and if the information could 
significantly influence their health care” 41.  
 
The guidelines of the American Academy of 
ediatrics on the use of genetic testing in P
children stipulate the need to limit the use of 
genetic tests for late-onset diseases during 
childhood, yet uphold the need for research 
in this area42.  
 
Finally, several other normative texts have 
rovided guidelines to frame the use of 
In ns are 
trict. Research involving children may be 
ubject of genetic 
research and minors recognize that, when a 
p
genetic tests, however, they do not 
specifically address predisposition genetic 
tests in research. These more general 
guidelines will not be discussed in this 
paper.     
    
2) Pediatric Genetic Research 
 
 pediatric research, the conditio
s
undertaken only if 1) the research in 
question could not take place on an adult 
population43, 2) the research is being 
undertaken in the best interests of the child 
(i.e. likelihood of direct benefit to the child) 
or, in exceptional cases, for the best 
interests of the group for which the child is a 
part44, and 3) the legal representative gives 
free and informed consent for the minor’s 
participation in the research project in 
question45.  Also, in cases where a research 
project does not directly benefit the child, the 
research may not expose the child to more 
than minimal risk46. However, it is also 
controversial whether genetic testing 
presents minimal risk47. 
Furthermore, the majority of normative texts 
with articles on the s
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child can understand the nature and 
consequences of the proposed research48, 
their opinion (assent) to participate in 
research decisions must be taken into 
account, and should be based on their age 
and level of maturity49. Some of these same 
normative texts stress the importance of 
respecting children’s dissent50, while others 
hold that it is necessary to take into account 
the dissent of minors51. The notion of 
hereditary disease risk is very complicated 
and its interpretation varies greatly among 
adults52. Therefore, the interpretation of 
hereditary disease risk will likely cause even 
greater difficulties for children.  
 
Finally, another important issue to consider 
is confidentiality. Since there are no specific 
gulations concerning confidentiality or the 
mplex because it rarely has a 
hort-term effect on the health of the child. It 
n measures 
aming the use of predisposition genetic 
re
communication of research results in 
pediatric research, it seems appropriate to 
apply the same limits applicable to adult 
genetic research to pediatric research.  It is 
important to highlight that if there are results 
to be given at the time or in the future, it is 
the parent who will receive the results, when 
the tested subject is a child. This obviates 
the child’s right not to know and raises 
issues of how and when children should be 
informed of the availability of this result. 
Generally, all personal information procured 
in research is confidential and should be 
treated in a manner that respects privacy53. 
Furthermore, research participants do not 
generally receive individual research results, 
as the purpose of research is to produce 
generalized knowledge. However, research 
participants have the right to be informed of 
such general results54 within a reasonable 
time55. In exceptional cases, where research 
reveals information which directly impacts 
on the current or future health of the 
research participants, informing the 
participants of the research results should 
be proposed56. However, it can be difficult, 
in both adult and pediatric genetic research 
to determine when the results are of clear 
clinical utility and, even when that is 
established, to know how to approach 
participants to ascertain if they are 
interested in learning their test result, either 
directly or though further clinical testing. 
Other complications include the fact that in a 
context where a result may have medical 
implications for more than one family 
member, the requirement to protect 
confidentiality may be challenging to 
balance against the rights of the other family 
members. Generally, third party access to 
genetic information is permitted only when 
the individual consents to this access57.  
Also, it is important to respect the 
participant’s right not to be informed58. 
      
Conclusion  
 
The use of predisposition tests in pediatric 
research is co
s
can be useful and beneficial, in the long-
term, for the health of the pediatric 
population as a whole. However, is this in 
the best interests of the child? 
 
Based on our analysis of normative texts, it 
seems that specific protectio
fr
tests in pediatric research are extremely 
limited. In fact, although there are provisions 
on the use of predisposition tests in 
research, they seem aimed principally at 
research carried out on adults. The 
guidelines regarding adult research are not 
sufficient to handle the complexities of 
children’s rights to confidentiality, the right 
not to know and the right to choose.  The 
need for specific norms that protect the 
rights and interests of children in research 
has been long recognized59. Moreover, the 
use of predisposition tests in minors raises 
specific issues. Consequently, it seems 
important to develop norms for the use of 
predisposition tests in pediatric research, 
particularly regarding questions about the 
best interests of the child and assent issues.  
 
Regarding assent, the Convention on the 
Rights of the Child states that adults must 
involve children in decisions that concern 
them60. Though the importance of including 
minors in the research decision process 
(assent) is recognized, there is a lack of 
uniformity as to how this requirement will be 
satisfied. In this regard, we suggest that the 
information document and assent process 
be adapted to the child’s language and 
comprehension level and be separate from 
the documents and consent process 
applicable to the parents. Second, 
considering the amount and the complexity 
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of the information specific to genetic 
research, it will be important to take into 
consideration children’s developmental and 
cognitive levels if research assent is to be 
expected. Third, there should be periodic 
review of assent, especially for longitudinal 
research, as the meaning of particular 
genetic information is likely to change with 
time. Overall, we believe that it is important 
to promote the active participation of young 
people in research: in others words, as 
partners in its different stages61.  
 
It is important that all pediatric research be 
guided by the best interests of the child, in 
onformity with the 1989 Convention on the 
s in the 
ediatric population received relatively little 
c
Rights of the Child. The duty to act in the 
best interests of the child requires us to 
ensure that each child be protected against 
research risks while also requiring that our 
actions, or non-actions, do not cause any 
harm to this population. Pediatric 
predisposition genetic testing research will 
probably not provide short-term medical 
benefits for the health of the child and there 
are potential psychosocial risks related to 
the communication of predisposition test 
results. These issues are noteworthy. We 
believe that to conform to the standards of 
the best interests of the child, specific rules 
are required for the confidentiality of 
predisposition test results in pediatric 
research. Moreover, if there are no 
treatment or effective preventive measures 
that can benefit the actual or future health of 
the child, there should be no disclosure of 
research test results (either to the child or to 
the parents) for the following reasons: it 
would not be in the best interests of the 
child, it would contravene the child’s rights to 
confidentiality and privacy, and it can have 
psychosocial consequences. However, if 
and when the predisposition test provides 
information that can be clinically validated, 
i.e. when it can be used to improve present 
and future health, and when the conditions 
currently governing the use of predisposition 
genetic tests in minors in the clinical context 
are met, then the research results should be 
communicated. In addition, we advocate the 
use of genetic counselling, prior to the 
communication of genetic information, and a 
well developed process of assent.  
 
At the beginning of the 1990s, the clinical 
use of predisposition genetic test
p
attention in the literature62 and in ethical and 
professional norms63. Today that situation 
has changed64. While the imperative for 
pediatric genetic research is there, none of 
the normative texts examined explicitly 
address the question of the use of 
predisposition tests in pediatric research65.  
We believe that there is a need for the 
development of guidelines specifically 
geared to the rights and interests of children 
as participants in genetic research. 
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